CSTL CASTLE BIOSCIENCES INC
Services-Medical Laboratories · Nasdaq · SEC CIK 1447362 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.8%
TTM net income YoY-88.1%
TTM EPS YoY-72.7%
Revenue 3-yr CAGR25.2%
Net income 3-yr CAGR—
Margins
Gross margin77.1%
Operating margin-7.4%
Net margin-6.1%
FCF margin1.1%
EBITDA margin-4.4%
Returns
ROE-4.9%
ROA-4.0%
ROIC (approx.)-5.5%
Asset turnover0.66x
Leverage & solvency
Liabilities / assets17.4%
Debt / equity0.02x
Current ratio5.28x
Interest coverage-51.16x
Cash quality & payout
Operating cash flow / net income-1.73x
Accruals ratio-11.0%
Payout ratio—
Capex / revenue9.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $102.89M | $103.55M | $83.68M | $87.01M | $83.04M | $86.19M | $87.99M | $86.31M |
| Cost of revenue | $23.92M | $23.70M | $20.53M | $18.32M | $18.70M | $17.63M | $16.38M | $16.18M |
| Gross profit | $78.97M | $79.85M | $63.15M | $68.69M | $64.34M | $68.56M | $71.61M | $70.13M |
| R&D expense | $15.81M | $14.54M | $14.43M | $13.52M | $12.96M | $12.79M | $12.59M | $11.77M |
| SG&A expense | $63.79M | $66.12M | $64.90M | $56.73M | $55.91M | $58.06M | $58.62M | $49.97M |
| Operating income | -$2.73M | -$3.07M | -$18.41M | -$3.83M | -$6.80M | -$4.25M | -$27.93M | $4.05M |
| Interest expense | $197,000 | $193,000 | $134,000 | $24,000 | $24,000 | $21,000 | $17,000 | $156,000 |
| Income tax | $298,000 | $370,000 | $109,000 | -$382,000 | $115,000 | -$4.67M | -$423,000 | -$1.71M |
| Net income | -$4.10M | -$2.06M | -$14.52M | -$2.33M | -$501,000 | $4.52M | -$25.85M | $9.59M |
| EBITDA | -$656,000 | -$1.25M | -$14.48M | -$50,000 | -$5.26M | -$2.80M | $1.84M | $9.82M |
| EPS (basic) | -0.13 | -0.07 | -0.49 | — | -0.02 | 0.16 | -0.90 | — |
| EPS (diluted) | -0.13 | -0.07 | -0.49 | — | -0.02 | 0.15 | -0.90 | — |
| Weighted avg. shares (diluted) | 30.63M | 30.40M | 29.89M | — | 29.07M | 29.55M | 28.61M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $77.99M | $62.12M | $63.76M | $116.73M | $85.56M | $82.23M | $89.69M | $119.71M |
| Short-term investments | $199.67M | $204.69M | $197.92M | $182.78M | $201.99M | $193.70M | $185.46M | $173.42M |
| Receivables | $52.10M | $48.34M | $42.26M | $43.38M | $49.48M | $52.31M | $56.35M | $51.22M |
| Inventory | $10.38M | $10.58M | $10.46M | $10.25M | $8.65M | $8.37M | $6.85M | $8.13M |
| Current assets | $356.86M | $341.10M | $328.90M | $361.10M | $357.57M | $348.67M | $349.39M | $360.15M |
| PP&E, net | $111.46M | $104.68M | $100.93M | $97.44M | $84.89M | $74.06M | $55.42M | $51.12M |
| Goodwill | $10.70M | $10.70M | $10.70M | $10.70M | $10.70M | $10.70M | $10.70M | $10.70M |
| Intangibles | $80.80M | $84.40M | $86.66M | $88.88M | $91.16M | $93.43M | $67.21M | $95.54M |
| Total assets | $579.41M | $561.18M | $547.80M | $578.56M | $562.79M | $544.73M | $501.71M | $531.24M |
| Current liabilities | $67.61M | $56.51M | $48.76M | $68.68M | $55.31M | $50.89M | $37.27M | $49.39M |
| Short-term debt | $4.17M | $2.92M | $1.67M | $417,000 | $0 | $1.94M | $1.11M | $278,000 |
| Long-term debt | $5.92M | $7.16M | $8.40M | $9.64M | $10.05M | $8.10M | $8.92M | $9.74M |
| Total debt | $10.08M | $10.07M | $10.07M | $10.06M | $10.05M | $10.04M | $10.03M | $10.02M |
| Total liabilities | $100.96M | $91.15M | $86.39M | $107.68M | $95.74M | $89.35M | $61.41M | $75.40M |
| Shareholders' equity | $478.44M | $470.03M | $461.42M | $470.87M | $467.05M | $455.38M | $440.31M | $455.83M |
| Net debt | -$67.91M | -$52.04M | -$53.70M | -$106.67M | -$75.51M | -$72.19M | -$79.66M | -$109.69M |
| Shares outstanding | 30.77M | 30.51M | 30.30M | 29.69M | 29.16M | 28.98M | 28.84M | 28.48M |
| Cash flow statement | ||||||||
| Operating cash flow | $19.74M | $15.20M | -$22.13M | $26.93M | $22.63M | $20.82M | -$6.04M | $24.36M |
| Capital expenditure | $7.49M | $8.65M | $12.46M | $7.18M | $14.83M | $9.26M | $4.74M | $7.57M |
| Free cash flow | $12.25M | $6.55M | -$34.58M | $19.75M | $7.80M | $11.56M | -$10.78M | $16.80M |
| Investing cash flow | -$4.73M | -$15.96M | -$25.80M | $8.83M | -$18.39M | -$28.38M | -$22.43M | $5.77M |
| Financing cash flow | $866,000 | -$886,000 | -$5.03M | -$4.59M | -$919,000 | $101,000 | -$1.55M | -$5.38M |
| Depreciation & amortization | $2.08M | $1.82M | $3.93M | $3.78M | $1.54M | $1.45M | $29.76M | $5.77M |
| Stock-based compensation | $11.23M | $11.59M | $9.78M | $11.41M | $12.10M | $11.21M | $11.18M | $11.44M |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.